Aspen Neuroscience

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
dopaminergic neuron replacementCell therapy
Parkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 March 2026PresentationSasineprocelASPIRO Phase 1/2a (NCT06344026) 12-month data at AD/PD 2026: open-label, n=8, engraftment with motor and quality-of-life signals

Financial reports

No financial reports recorded.